Shares of Tempus AI (TEM) surged 15% on Thursday after Chief Executive Officer Eric Lefkofsky presented Medicare reimbursement projections for the company's diagnostic pipeline at the Morgan Stanley 24th Annual Global Healthcare Conference. The gain extended the healthcare technology company's rally to nearly 40% across the last five trading sessions and left the stock approaching its strongest close since November 2025.

Tempus AI, a precision medicine company that applies artificial intelligence to genomic and clinical data, listed on the Nasdaq in June 2024. Its shares have now staged a remarkable recovery after a difficult summer.

During the presentation, Lefkofsky outlined expectations for $80 million to $100 million in reimbursements next year from the company's solid tumor tissue scanning diagnostic. He additionally forecast $250 million to $300 million in revenue potential from Tempus' liquid biopsy offering — a method that detects cancer signals from a blood sample rather than surgically removed tissue — pending regulatory approval that the company anticipates in the latter half of 2027. For diagnostics developers, Medicare reimbursement figures serve as a barometer of commercial traction, since they indicate how much revenue a test can generate once gains coverage. The revenue guidance provided investors with the confidence needed to return to the stock following a challenging period that began with the company's July acquisition news.

In July, Tempus announced plans to purchase cancer diagnostics firm Personalis for $1.5 billion, or $16.25 per share, compensated primarily through stock. Stock-funded structures of this kind can weigh on shares because they expand a company's share count, and the market's initial reaction to the deal was negative, driving TEM shares lower. Since bottoming at a 52-week low of $41.55 on July 29, however, the stock has rebounded 92%, reversing the decline that followed the deal announcement.

Data Licensing Powers Expansion

Beyond its diagnostic offerings, Lefkofsky emphasized the data licensing division as a critical growth catalyst. The segment expanded 36% in the most recent quarter and features multi-year agreements valued above $100 million each with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb, GSK, Merck and BioNTech — a roster that reflects how centrally large-scale clinical datasets now figure in drug development. According to Lefkofsky, Tempus maintains a database encompassing 50 million patients alongside established partnerships with hospitals and pharmaceutical firms, providing a competitive advantage in the data licensing arena.

The pending Personalis transaction is anticipated to bolster Tempus' molecular residual disease capabilities — tests that search for traces of cancer remaining in the body after treatment — while driving test pricing beyond $1,000 per test in the future.

For the second quarter ended July 30, Tempus disclosed revenue of $382.5 million, with the diagnostics division accounting for 76% of total sales. The company also highlighted $200 million in fresh licensing contracts within its data and applications division, underscoring the growing weight of diagnostics and data services in its overall business.

Analyst Perspective

Notwithstanding the recent surge, the Street's consensus target price stands at $66.56, now indicating approximately 17% downside from current trading levels. TEM maintains a Moderate Buy rating supported by 10 Buy recommendations and 7 Hold ratings issued over the past three months — a split showing analyst opinion remains divided even as shares rally.

Addressing concerns about the stock's rapid ascent, Lefkofsky dismissed suggestions of overvaluation. He emphasized the company's commitment to achieving 25% annual growth throughout the next decade rather than fixating on near-term volatility. “If you got to bet at all, every day of the week and twice on Sunday, we over-deliver,” he stated.

ARK Innovation ETF (ARKK), which maintains TEM as its third-largest holding after Tesla and SpaceX, advanced 4.3% on Thursday. ARK Invest had accumulated approximately 85,000 TEM shares in March while reducing its Meta allocation.

Over the past month, TEM has climbed more than 60%, and the stock's current five-day winning streak represents its most robust performance since the July trough. From here, investors are likely to watch the tissue diagnostic's reimbursement ramp next year, the liquid biopsy regulatory decision expected in the latter half of 2027, and the completion of the pending Personalis acquisition.

This article originally appeared on Blockonomi.